ELISA-VIDITEST anti-Borrelia recombinant kits are intended for the detection of IgG and IgM antibodies to the pathogenic borrelia strains (B.afzelii, B. garinii and B. burgdorferi sensu stricto) in human serum, cerebrospinal fluid and synovial fluid. The detection of antibodies is one of the laboratory tests that help to diagnose Lyme disease (LD).
Anti-borrelia IgM antibodies are detectable 3 weeks after infection with its maximum during the sixth week. Subsequently, the titre of IgM antibodies decreases and the IgG antibodies prevail. The detection of anti-borrelia antibodies is very important at the early stage of the disease since the typical symptoms are present only in a certain proportion of patients (e.g. erythema migrans is present in 50% of patients). The clinical symptoms of LD are similar to the symptoms in other diseases, therefore the serology is also of use in differential diagnosis of neuroinfections, arthropathies, carditis and skin diseases.
LIA-VIDITEST anti-Borrelia kits are line immunoassays intended for qualitative detection of specific IgG and IgM antibodies to antigens of major pathogenic Borrelia stains (B. afzelii, B. garinii a B. burgdorferi sensu stricto) and Anaplasma phagocytophilum in human serum. The kits are used to confirm the ELISA results during the serological diagnostics of Lyme disease. The kits can be also used to an indicative diagnostics of Human granulocytic anaplasmosis (HGA). HGA is caused by bacterium Anaplasma phagocytophilum, which attacks white blood cells (granulocytes). Anaplasma infection can result in death for immunodeficient, post-splenectomy or post-transplant patients. Anaplasma-specific antibodies are detected in human serum by high-specific antigen p44.
ELISA-VIDITEST anti-C6 is an ELISA kit for the detection of anti-C6 antibodies in human serum. C6 is a highly specific conserved immunodominant 26 aminoacid peptide derived from VlsE – outher surface lipoprotein of Borrelia burgdorferi.